Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Clin Cancer Res. 2010 Feb 1;16(3):867-75. doi: 10.1158/1078-0432.CCR-09-1840. Epub 2010 Jan 26.
This study aims to profile the expressions of 156 microRNAs (miRNA) in hepatocellular carcinoma (HCC) and to characterize the functions of miR-222, the most significantly upregulated candidate identified.
miRNA expression profile in HCC tumors, matching adjacent cirrhotic livers, and cell lines was conducted using quantitative PCR. Common miR-222 upregulations were further validated in a larger cohort of tumors. The functional effects of miR-222 inhibition on HCC cell lines were examined. The downstream modulated pathways and target of miR-222 were investigated by coupling gene expression profiling and pathway analysis, and by in silico prediction, respectively. Luciferase reporter assay was done to confirm target interaction.
We identified a 40-miRNA signature that could discriminate tumors from adjacent cirrhotic liver tissue, and further corroborated common miR-222 overexpression in tumors relative to its premalignant counterpart (55.3%; P < 0.0001). Increased miR-222 expression correlated significantly with advanced stage HCC and with the shorter disease-free survival of patients (P < or = 0.01). Inhibition of miR-222 in Hep3B and HKCI-9 significantly retarded cell motility (P < 0.05). Further investigations suggested that AKT signaling was the major pathway influenced by miR-222. A consistent reduction of AKT phosphorylation in Hep3B and HKCI-9 was shown following miR-222 suppression. The protein phosphatase 2A subunit B (PPP2R2A) was predicted as a putative miR-222 target in silico. We found that miR-222 inhibition could augment the tumor protein level and restore luciferase activity in reporter construct containing the PPP2R2A 3' untranslated region (P = 0.0066).
Our study showed that miR-222 overexpression is common in HCC and could confer metastatic potentials in HCC cells, possibly through activating AKT signaling.
本研究旨在描绘肝细胞癌(HCC)中 156 种 microRNA(miRNA)的表达谱,并对鉴定出的上调最显著的候选 miRNA-222 的功能进行研究。
采用定量 PCR 法对 HCC 肿瘤、匹配的肝硬化肝脏和细胞系中的 miRNA 表达谱进行检测。在更大的肿瘤队列中进一步验证常见的 miR-222 上调。通过基因表达谱分析和通路分析,以及计算机预测,分别检测 miR-222 抑制对 HCC 细胞系的功能影响。采用荧光素酶报告基因检测证实靶基因相互作用。
我们确定了一个 40-microRNA 特征谱,可将肿瘤与相邻肝硬化组织区分开,并且进一步证实了肿瘤相对于其癌前组织中常见的 miR-222 过表达(55.3%;P < 0.0001)。miR-222 表达增加与 HCC 晚期分期和患者无病生存率较短显著相关(P < 0.01)。抑制 Hep3B 和 HKCI-9 中的 miR-222 显著延缓了细胞迁移(P < 0.05)。进一步的研究表明,AKT 信号通路是受 miR-222 影响的主要通路。抑制 miR-222 后,在 Hep3B 和 HKCI-9 中均观察到 AKT 磷酸化明显减少。计算机预测蛋白磷酸酶 2A 亚基 B(PPP2R2A)是 miR-222 的一个潜在靶基因。我们发现,抑制 miR-222 可增加肿瘤蛋白水平,并恢复含有 PPP2R2A 3'非翻译区的报告构建体的荧光素酶活性(P = 0.0066)。
本研究表明,miR-222 在 HCC 中过度表达较为常见,可能通过激活 AKT 信号通路,赋予 HCC 细胞转移潜能。